Evogene (EVGN) Stock News

Biomica, a clinical-stage biopharmaceutical company and subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced its participation in the 2023 ECCO Annual Meeting in Copenhagen, Denmark, from March 1 to 4, 2023. The conference focuses on advancements in Inflammatory Bowel Diseases (IBD). Professor Yehuda Ringel, Biomica's CSO, will present a poster titled "Anti-inflammatory Effect and Mechanism of Action of BMC333" during the conference on March 3, 2023. The poster will be accessible until June 4, 2023, and Professor Ringel is available for one-on-one meetings throughout the event.

Evogene Ltd. (NASDAQ: EVGN) will participate in the 35th Annual ROTH Conference in Dana Point, California, on March 13-14, 2023. The event will include one-on-one meetings, industry panels, and presentations, attracting institutional investors and analysts. Executive VP Eyal Ronen will be available for discussions with investors on March 13. Interested investors can arrange meetings through Roth representatives or Evogene's investor relations team, which offers both in-person and virtual options. Evogene focuses on computational biology to enhance the development of life-science products through innovative technologies like MicroBoost AI, ChemPass AI, and GeneRator AI.

Lavie Bio Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced successful results from field trials of its bio-fungicides, LAV311 and LAV321, conducted in 2022. These products aim to combat fungal diseases like bunch rot and blight while reducing chemical reliance in agriculture. The bio-fungicides showed improved efficacy over existing commercial benchmarks, paving the way for potential commercialization in 2024, pending EPA registration. Lavie Bio's advancements cater to the growing demand for eco-friendly solutions in agriculture amidst an estimated $21 billion global fungicide market, projected to grow at a CAGR of 6.4%.

Evogene Ltd. (NASDAQ: EVGN) announced it will release its financial results for the fourth quarter and full year 2022 on March 9, 2023. A conference call is scheduled for 9am ET that same day, where management will discuss the results. The company focuses on utilizing advanced computational biology technologies to enhance life-science product development. Evogene operates through subsidiaries, developing products in areas like human microbiome therapeutics and ag-chemicals.

For investors, the call can be accessed via telephone or live webcast on the company's website.

Canonic Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN), has successfully launched six second-generation hybrid cannabis products in Israel. These products, leveraging Evogene's GeneRator AI tech-engine, feature high THC levels ranging from 23% to 24.4%, maximizing psychoactive potential. The new offerings include Synergy, Combo, Mosaic, Two Stars, Mash Kush, and Blend Kush. Developed through innovative breeding techniques, these cannabis strains aim to meet market demands for specific medical effects. Looking ahead, Canonic plans to develop third-generation products and expand into European markets.

Biomica Ltd., a clinical-stage biopharmaceutical company and a subsidiary of Evogene (NASDAQ: EVGN), announced that its CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner will attend the 7th Annual Microbiome Movement Drug Development Europe in London from January 31 to February 2, 2023. Dr. Haber will participate in two panel discussions, focusing on translating microbiome science into products and investor collaboration. Dr. Meshner's presentation, entitled Rationally Designed LBPs – From Computational & Pre-clinical Data to Clinical Studies, is scheduled for February 1, 2023. Both executives are available for one-on-one meetings at the conference.

Casterra Ag Ltd., a subsidiary of Evogene (Nasdaq: EVGN), has entered an agreement with a leading energy company to supply unique castor seed varieties for biofuel production. The primary focus includes seed purchases for cultivation in specific African territories, with the possibility of expanding cooperation. Castor biofuels are noted for their renewable, biodegradable properties and minimal environmental impact, being carbon-neutral. Casterra aims to provide genetically advanced seeds to meet eco-friendly energy needs, leveraging Evogene's GeneRator AI tech-engine for high-yield crops. This partnership could enhance Casterra's market position in the biofuel sector.

Biomica Ltd., a biopharmaceutical company under Evogene Ltd. (NASDAQ: EVGN), will participate in the J.P. Morgan Healthcare Week from January 9 to 11, 2023, in San Francisco. This follows a successful financing round of $20 million led by Shanghai Healthcare Capital. Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings.

Biomica focuses on developing microbiome-based therapeutics for antibiotic resistance, immuno-oncology, and gastrointestinal disorders, utilizing a unique Computational Predictive Biology platform.

Biomica Ltd., a clinical-stage biopharmaceutical company and subsidiary of Evogene (Nasdaq: EVGN), announced a $20 million financing round led by Shanghai Healthcare Capital. This funding is essential for advancing Biomica's pipeline of microbiome-based therapeutics, including completing the phase 1 study of BMC128 and preparing for phase 1 trials of BMC333 aimed at treating inflammatory bowel disease. The financing is pending clearance from Chinese regulatory authorities.